The changing clinical spectrum of endocrine adverse events in cancer immunotherapy

Sabrina Chiloiro*, Antonio Bianchi, Antonella Giampietro, Domenico Milardi, Laura De Marinis Grasso, Alfredo Pontecorvi

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several malignancies, improving patient survival and quality of life. Endocrinopathies have emerged as a clinically significant group of immune-related adverse events (IRAEs). Although the mechanism of ICI toxicities has not been clarified, inhibition of immune checkpoints reduces immune tolerance to autoantigens, resulting in the development of autoimmunity disorders. We report current evidence regarding endocrine IRAEs that may have diagnostic and therapeutic implications. Management should be focused on a multidisciplinary approach to reach a prompt diagnosis and an appropriate and safe treatment.
Lingua originaleEnglish
pagine (da-a)87-104
Numero di pagine18
RivistaTrends in Endocrinology and Metabolism
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • adrenal insufficiency

Fingerprint

Entra nei temi di ricerca di 'The changing clinical spectrum of endocrine adverse events in cancer immunotherapy'. Insieme formano una fingerprint unica.

Cita questo